Stem Cell Therapy For Multiple Sclerosis Market Report 2026

Stem Cell Therapy For Multiple Sclerosis Market Overview

• Stem Cell Therapy For Multiple Sclerosis market size has reached to $1.82 billion in 2025 • Expected to grow to $3.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.2% • Growth Driver: Surge In Multiple Sclerosis Cases Fueling Growth Due To Improving Diagnosis And Awareness • Market Trend: Advancements In Autologous Mesenchymal Stem Cell Therapies For Multiple Sclerosis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Stem Cell Therapy For Multiple Sclerosis Market?

Stem cell therapy for multiple sclerosis is a regenerative medical approach that uses stem cells to repair nerve damage and restore immune system balance in patients with multiple sclerosis, an autoimmune disorder that attacks the protective myelin sheath around nerve fibers. The therapy aims to stop disease progression, reduce inflammation, and promote regeneration of damaged nervous tissue. The main components of stem cell therapy for multiple sclerosis are embryonic stem cells, adult stem cells, induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells. Stem cell therapy for multiple sclerosis using embryonic stem cells involves transplanting pluripotent cells derived from early-stage embryos to repair damaged myelin and promote neural regeneration. The various treatment approach include autologous stem cell therapy, allogeneic stem cell therapy. The delivery method includes intravenous injection, intrathecal injection, direct intraspinal administration. The applications include relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), progressive relapsing multiple sclerosis (PRMS). The various end-users include hospitals, specialty clinics, research institutes, others.

What Is The Stem Cell Therapy For Multiple Sclerosis Market Growth Forecast?

The stem cell therapy for multiple sclerosis market size is expected to see rapid growth in the next few years. It will grow to $3.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing long-term efficacy data for stem cell therapies, rising demand for disease-modifying treatments, expansion of personalized neurology care, growing investments in neuro-regenerative research, increasing collaboration between hospitals and research institutes. Major trends in the forecast period include increasing adoption of autologous hematopoietic stem cell transplants, growing focus on immune system reset therapies, rising adoption of mesenchymal stem cell applications, increasing use of targeted delivery methods, enhanced clinical monitoring and outcome tracking.

Global Stem Cell Therapy For Multiple Sclerosis Market Segmentation

1) By Type Of Stem Cell: Embryonic Stem Cells, Adult Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Hematopoietic Stem Cells 2) By Treatment Approach: Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy 3) By Delivery Method: Intravenous Injection, Intrathecal Injection, Direct Intraspinal Administration 4) By Application: Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS) 5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users Subsegments: 1) By Embryonic Stem Cells: Inner Cell Mass Cells, Blastocyst Derived Cells, Totipotent Stem Cells 2) By Adult Stem Cells: Bone Marrow Stem Cells, Neural Stem Cells, Tissue Specific Stem Cells 3) By Induced Pluripotent Stem Cells: Reprogrammed Somatic Cells, Patient Derived Cells 4) By Mesenchymal Stem Cells: Adipose Derived Stem Cells, Umbilical Cord Derived Stem Cells, Bone Marrow Derived Stem Cells 5) By Hematopoietic Stem Cells: Peripheral Blood Stem Cells, Bone Marrow Stem Cells, Umbilical Cord Blood Stem Cells

What Is The Driver Of The Stem Cell Therapy For Multiple Sclerosis Market?

The increasing prevalence of multiple sclerosis (MS) is expected to contribute significantly to the growth of the stem cell therapy for multiple sclerosis market going forward. Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system by damaging the protective myelin sheath surrounding nerve fibers, leading to impaired communication between the brain and body and causing symptoms such as fatigue, muscle weakness, and vision problems. The rising prevalence of MS is primarily attributed to improved diagnostic capabilities, as advances in medical imaging and heightened awareness enable more accurate and earlier identification of cases, resulting in higher reported numbers. Stem cell therapy for multiple sclerosis aids in repairing damaged myelin, modulating abnormal immune responses, and promoting nerve cell regeneration, thereby helping to reduce symptoms and potentially slow disease progression. For instance, in May 2024, according to a report published by the MS Trust, a UK-based organization, approximately 2.9 million people worldwide are affected by multiple sclerosis, including over 150,000 individuals living with the condition in the UK. Therefore, the increasing prevalence of multiple sclerosis is expected to drive the expansion of the stem cell therapy for multiple sclerosis industry.

Key Players In The Global Stem Cell Therapy For Multiple Sclerosis Market

Major companies operating in the stem cell therapy for multiple sclerosis market are Sana Biotechnology Inc., Century Therapeutics Inc., Reelabs Private Limited, PlacidWay LLC, MedAccess Guarantee Ltd, Celltex Therapeutics Corporation, CELLTEX THERAPEUTICS CORP, BrainStorm Cell Therapeutics Ltd., Athersys Inc., Advancells Dermaceuticals Private Limited, ImStem Biotechnology Inc., NeuroGenesis Bio Inc., Stem Cell Medicine Ltd., Biotherapy International, R3 Stem Cell, Hope Biosciences LLC, FibroBiologics Inc., Global Institute of Stem Cell Therapy and Research Inc., ProgenCell, Stemwell

Global Stem Cell Therapy For Multiple Sclerosis Market Trends and Insights

Major companies operating in the stem cell therapy for multiple sclerosis market are focusing on developing innovative products, such as adipose-derived mesenchymal stem cells, to enhance the efficacy, safety, and regenerative potential of treatments for patients with relapsing-remitting and progressive forms of multiple sclerosis. Adipose-derived mesenchymal stem cells (ADMSCs) are multipotent stem cells derived from adipose (fat) tissue that can differentiate into multiple cell types and exhibit regenerative and immunomodulatory properties beneficial in treating autoimmune and neurodegenerative diseases such as multiple sclerosis. For instance, in August 2025, Hope Biosciences, LLC, a US-based biopharmaceutical company, introduced its HB-adMSCs therapy, which utilizes adipose-derived mesenchymal stem cells administered through high-dose infusions and repeat dosing over a 32-week period. The therapy combines immunomodulatory and neuroregenerative mechanisms, offering the potential to slow disease progression and repair myelin damage, distinguishing it from conventional immunosuppressive treatments.

What Are Latest Mergers And Acquisitions In The Stem Cell Therapy For Multiple Sclerosis Market?

In November 2024, Pluri Inc., an Israel-based biotechnology company, partnered with Brainstorm Cell Therapeutics Ltd. Through this partnership, Pluri Inc. aims to advance the development and commercialization of innovative regenerative therapies in collaboration with Brainstorm Cell Therapeutics Ltd., leveraging their combined expertise to accelerate clinical research and improve treatment outcomes for patients. Brainstorm Cell Therapeutics Ltd. is a US-based biotechnology company that provides stem cell therapy for multiple sclerosis.

Regional Outlook

North America was the largest region in the stem cell therapy for multiple sclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Stem Cell Therapy For Multiple Sclerosis Market?

The stem cell therapy for multiple sclerosis market includes revenues earned by providing services such as stem cell collection and processing services, cryopreservation and storage services, patient preconditioning services, post-therapy rehabilitation services, and immune system profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Stem Cell Therapy For Multiple Sclerosis Market Report 2026?

The stem cell therapy for multiple sclerosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy for multiple sclerosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.